You just read:

Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis

News provided by

AbbVie

Jun 05, 2018, 08:30 ET